Lancet Oncology

Oncology & Cancer

Immune-targeting drug combo shows promise for lung cancer patients

Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new and improved treatment ...

Oncology & Cancer

3-D mammography detected 34% more breast cancers in screening

In traditional mammography screening, all breast tissue is captured in a single image. Breast tomosynthesis, on the other hand, is three-dimensional and works according to the same principle as what is known as tomography. ...

Oncology & Cancer

Clinical trials show promise in leukemia

Two drugs that target different mutations showed encouraging results in treating leukemia, according to recent clinical trials published in the New England Journal of Medicine (NEJM) and The Lancet Oncology.

Oncology & Cancer

Cancer incidence predicted to increase 75 percent by 2030

The global cancer burden is set to surge more than 75% by 2030, according to new research published Online First in the Lancet Oncology. The rise is predicted to be even larger in the developing world, with the poorest countries ...

Oncology & Cancer

New blood test improves prostate cancer screening

Researchers at Karolinska Institutet in Sweden recently reported that magnetic resonance imaging (MRI) could reduce overdiagnoses and thereby improve prostate cancer screening. Now, the same research group has published a ...

page 7 from 39